EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

[Translated article] Cost of Treating Cutaneous T-Cell Lymphoma in Spain: Analysis of MICADOS Study Data by Disease Stage

B Navarro Matilla, P L Ortiz Romero, R M Pujol Vallverdú, A Combalia Escudero, I Zapata Paz, E González Barca, C Muniesa Montserrat, M Morillo Andújar, A Pérez Ferriols, C Román Curto, R Fernández de Misa Cabrera, M Hospital Gil und 13 weitere

Actas Dermo-Sifiliográficas · 2024

DOI: 10.1016/j.ad.2023.11.017 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Actas Dermo-Sifiliográficas, 2024. Verfasst von B Navarro Matilla und 24 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Hematología, Hospital Universitario Puerta de Hierro, Madrid, Spain. Hauptthemen laut MEDLINE: Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides, Sezary Syndrome, Skin Neoplasms. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Kyowa Kirin Farmacéutica.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVE: The cost of treating cutaneous T-cell lymphoma (CTCL) in Spain is unknown. With the advent of new treatments, it is more important than ever to gain an accurate picture of the true costs involved. The MICADOS study had 2 primary objectives: 1)to evaluate the impact of CTCL on patient quality of life, and 2)to evaluate the costs associated with the disease. This article reports the results of the cost analysis. METHODS: We estimated the cost of treating CTCL over a period of 1year from the perspective of the Spanish National Health System. Twenty-three dermatologists and hematologists from 15 public hospitals analyzed data for adult patients with mycosis fungoides (MF) or Sézary syndrome (SS). RESULTS: A total of 141 patients (57.4% male) with a mean age of 63.6 years (95%CI: 61.4-65.7 years) were included. The mean direct annual cost of treating CTCL was €34,214 per patient. The corresponding costs by stage were €11,952.47 for stageI disease, €23,506.21 for stageII disease, €38,771.81 for stageIII disease, and €72,748.84 for stageIV disease. The total direct annual cost of treating MF/SS in public hospitals in Spain was estimated at €78,301,171; stageI disease accounted for 81% of all costs, stageII for 7%, and stagesIII andIV for 6% each. CONCLUSIONS: The MICADOS study offers an accurate picture of the direct cost of treating CTCL in patients with MF/SS in Spain and shows that costs vary significantly according to disease stage. Patient-borne and indirect costs should be analyzed in future studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, T-Cell, CutaneousMycosis FungoidesSezary SyndromeSkin NeoplasmsHumansMaleFemaleMiddle AgedAgedQuality of LifeSpain

Stichwörter der Autor:innen

Cost of diseaseCoste de la enfermedadFarmacoeconomíaMicosis fungoidesMycosis fungoidesPharmacoeconomicsSézary syndromeSíndrome de Sézary

Autor:innen und Institutionen

  • Departamento de Hematología, Hospital Universitario Puerta de Hierro, Madrid, Spain.
  • Departamento de Dermatología, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Departamento de Dermatología, Hospital del Mar, Barcelona, Spain.
  • Departamento de Dermatología, Hospital Universitario Clínic i Provincial, Barcelona, Spain.
  • Departamento de Radiación Oncológica, Hospital Universitario Puerta de Hierro, Madrid, Spain.
  • Departamento de Hematología, Institut Catalá d'Oncología, Hospitalet de Llobregat, Barcelona, Spain.

Förderung

  • Kyowa Kirin Farmacéutica

Zitieren

APA

Navarro Matilla, B., Ortiz Romero, P. L., Pujol Vallverdú, R. M., Combalia Escudero, A., Zapata Paz, I., González Barca, E., Muniesa Montserrat, C., Morillo Andújar, M., Pérez Ferriols, A., Román Curto, C., Fernández de Misa Cabrera, R., Hospital Gil, M., Marín Niebla, A., Rios Rull, P. J., de la Cruz Vicente, F., Izu Belloso, R. M., Martín García-Sancho, A., Parera Amer, M. E., Córdoba Mascuñano, R., …, & Blanco Garnelo, J. (2024). [Translated article] Cost of Treating Cutaneous T-Cell Lymphoma in Spain: Analysis of MICADOS Study Data by Disease Stage. Actas Dermo-Sifiliográficas. https://doi.org/10.1016/j.ad.2023.11.017

Vancouver

Navarro Matilla B, Ortiz Romero PL, Pujol Vallverdú RM, Combalia Escudero A, Zapata Paz I, González Barca E, et al. [Translated article] Cost of Treating Cutaneous T-Cell Lymphoma in Spain: Analysis of MICADOS Study Data by Disease Stage. Actas Dermo-Sifiliográficas. 2024. doi:10.1016/j.ad.2023.11.017

BibTeX
@article{NavarroMatilla2024,
  author = {Navarro Matilla, B and Ortiz Romero, P L and Pujol Vallverdú, R M and Combalia Escudero, A and Zapata Paz, I and González Barca, E and Muniesa Montserrat, C and Morillo Andújar, M and Pérez Ferriols, A and Román Curto, C and Fernández de Misa Cabrera, R and Hospital Gil, M and Marín Niebla, A and Rios Rull, P J and de la Cruz Vicente, F and Izu Belloso, R M and Martín García-Sancho, A and Parera Amer, M E and Córdoba Mascuñano, R and Ramón Quiles, M D and Saus Carreres, A and Del Campo García, R and Machan, S and Viguera Ester, P and Blanco Garnelo, J},
  title = {[Translated article] Cost of Treating Cutaneous T-Cell Lymphoma in Spain: Analysis of MICADOS Study Data by Disease Stage},
  journal = {Actas Dermo-Sifiliográficas},
  year = {2024},
  doi = {10.1016/j.ad.2023.11.017}
}
Kostenlos starten →